BioView Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • BioView's estimated annual revenue is currently $12.8M per year.(i)
  • BioView's estimated revenue per employee is $251,000

Employee Data

  • BioView has 51 Employees.(i)
  • BioView grew their employee count by -6% last year.

BioView's People

NameTitleEmail/Phone
1
VP MarketingReveal Email/Phone
2
VP OperationsReveal Email/Phone
3
Service ManagerReveal Email/Phone
4
Lead Application Engineer | Operations & Logisitics ManagerReveal Email/Phone
5
West Coast Service Engineer ManagerReveal Email/Phone
6
Application EngineerReveal Email/Phone
7
Service and application engineerReveal Email/Phone
8
Application EngineerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$9.8M393%N/AN/A
#2
$8.5M343%N/AN/A
#3
$3M12-29%N/AN/A
#4
$5630M7477-11%$450MN/A
#5
$4.5M186%N/AN/A
#6
$7.2M5727%$29.6MN/A
#7
$14.3M57-12%N/AN/A
#8
$2.3M186%$44MN/A
#9
$40.7M162-1%N/AN/A
#10
$45.7M182-5%N/AN/A
Add Company

What Is BioView?

Our Mission is to improve cancer patient’s assessments and outcomes. BioView develops, manufactures, and markets innovative Automated cell imaging and analysis platforms for use in cytology, cytogenetics and pathology at clinical and research laboratories who wish to digitize and streamline their analysis workflow. BioView’s industry-leading platforms offer advanced capabilities for Fluorescent and Bright-field based applications driven by Artificial intelligence. Starting from automated FISH Analysis of tissue and cells suspension for cancer and genetic abnormalities, to automated whole slide imaging for digital pathology and quantitative IHC scoring application for nuclear & membrane staining. Bringing liquid Biopsy to the clinical Practice We are a world leader in providing solutions for Circulating tumor cells detection, enumeration and characterization. Our all-in-one DeNovo system, offers high levels of speed, standardization and sensitivity. It is easy to operate, and can be integrated with any CTC enrichment method, as well as any combination of immunofluorescence and FISH markers. NGK – New Generation Karyotyping An innovative platform powered by deep learning dramatically enhances technician efficiency and productivity and introduces first of a kind supervisor monitoring tools and an ISCN results generator that is directly linked to an online supporting cytogenetics database. Our customers leverage offline analysis and Web-based applications to collaborate with their colleagues and explore new business opportunities.

keywords:N/A

N/A

Total Funding

51

Number of Employees

$12.8M

Revenue (est)

-6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.4M556%N/A
#2
$16.5M56-2%N/A
#3
$7.5M6015%N/A
#4
$15.9M617%N/A
#5
$7.8M62-5%N/A